Internal radiotherapy with bone-seeking agents is effective in delivering high doses of radiation to widespread metastatic bone lesions and may limit the radiation absorbed dose to healthy tissue. Beta emitter have long been preferred agents for bone pain palliation. The approval of 223Ra and data showing a prolonged survival with alpha emitter are favored in […]
More information coming soon Learning Objectives Target Audience Faculty Registration Details
The course aims to provide the participants with basic knowledge regarding nuclear and molecular medical imaging in the neurological field. In particular, cerebral SPET and PET will be addressed. Learning Objectives Target Audience Nuclear medicine specialists with little or no experience in reading SPET and PET neurological imaging. Faculty Registration Details
The course is designed for Technologists and Nurses to enhance their expertise in applying radiopharmaceuticals for AD and MCI diagnosis in nuclear medicine. Participants will learn radiation protection principles, radiolabelling procedures, and waste management. The program also covers novel PET radiotracers for molecular diagnosis of neurocognitive disorders. Additionally, the course addresses patient and caregiver management […]
The GMP guidelines provide minimum requirements that a manufacturer of radiopharmaceuticals must meet to assure that their products are consistently high in quality, from batch to batch, for clinical use. The Basics of cGMP is a 2 days on-site ESMIT course, providing guidance through EU-cGMP regulation for manufacturing, testing, and quality assurance of radiopharmaceuticals in order to […]
Inflammation comes from the Latin word inflammare, to ignite or to set on fire – we want to ignite your interest in imaging inflammation and infection. Inflammatory and infectious diseases can be clinically challenging. Many are systemic with highly variable clinical presentations and sometimes vague and non-specific symptoms and findings. Association with implanted material like […]
Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women, being the fourth globally regardless of gender. By 2040, breast cancer is predicted to increase to over 3 million new cases and 1 million […]
This intensive 1,5-day course bridges the gap between radiobiology, dosimetry, and clinical practice in targeted radionuclide therapy. Designed for early-career nuclear medicine physicians and medical physicists, the programme explores dose-response relationships in the three most commonly used theranostic molecules: somatostatin-ligands for neuroendocrine tumours, PSMA-inhibitors for prostate cancer, and radioiodine for thyroid malignancies. Through a balanced […]
This 1,5-day course focuses on the growing field of integrated imaging in infectious and inflammatory diseases in children, with an emphasis on hybrid imaging. The panelists will introduce the participants to the specific aspects of paediatric patients in this growing field, covering the most relevant topics of the clinical scenario and the technical options available […]
"Bringing Therapy Radioisotopes into Clinical Radiopharmacy" is an advanced course designed to bridge the gap between isotope production, radiopharmaceutical preparation and clinical application. This course focuses on the practical and regulatory hurdles of integrating therapeutic radionuclides into hospital settings. Diving into production and purification methods of emerging therapeutic isotopes, supply chain and matched pairs for theranostics, […]
This onsite course on FDG PET/CT in multiple myeloma is a focused, practice-oriented training programme designed to enhance expertise in metabolic imaging of plasma cell disorders. The course integrates concise lectures, case discussions, and supervised workstation-based interpretation to provide immersive, hands-on learning.The programme includes a review of the pathophysiology of multiple myeloma and the biological […]
Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used for the diagnosis (i.e., staging and restaging) and treatment of patients with prostate cancer. Radionuclide PSMA therapy is a useful new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and potentially also in patients with hormone-sensitive prostate cancer. The course will cover the spectrum of […]
